In direct compression processing, the amidocarb particle size distribution determines blend endpoint precision in a 600 L bin blender rotating at 10 rpm for 15 min. Median particle size is controlled between 30 µm and 80 µm via Sympatec Helos laser diffraction; a coarse fraction above 150 µm increases percolation-driven segregation when combined with spray-dried lactose having bulk density below 0.55 g/cm³. Published compaction data for amidocarb alone is limited, so a 3 × 3 factorial pilot matrix is used to verify the lubrication window. A representative 100 mg tablet platform contains 33.3 wt% amidocarb, 44.7 wt% lactose monohydrate, 15.0 wt% microcrystalline cellulose PH-102, 5.0 wt% crospovidone Type A, and 2.0 wt% magnesium stearate. Compression on a 16-station rotary press is maintained between 12 kN and 18 kN; tablet hardness is measured on a Schleuniger 8M hardness tester with a release target of 80 N to 120 N. The process conflict is magnesium stearate over-lubrication: total blend times exceeding 8 min at 2.0 wt% stearate reduce compact hardness by 25–40% because the API surfaces become coated and interparticulate bonding declines. Dissolution testing under USP 711 uses 0.1 N HCl with 0.5% sodium lauryl sulfate at 37 ± 0.5 °C, paddle speed 75 rpm; immediate-release tablets show not less than 75% release at 45 min. Uniformity of dosage units is assessed according to USP 905, with an acceptance value not exceeding 15.0. The end product is a round biconvex 8 mm tablet packaged in PVC/PVDC/aluminum blisters at 25 °C/60% RH.

What Terminal Steam Autoclaving Requires from an Aqueous Amidocarb Batch

Terminal steam autoclaving of aqueous amidocarb solutions is not a default option; the thermal stability window must be established by forced-degradation analysis before cycle selection. When a 10 mg/mL formulation in Water for Injection is buffered with 50 mM acetate at pH 6.0, a standard cycle of 121 °C for 15 min according to Ph. Eur. 5.1.1 may be acceptable only if assay loss is ≤ 2.0% and individual unspecified degradation products remain ≤ 0.2%. If published data for amidocarb-specific thermal degradation in this configuration is limited, a development run at 105 °C for 4 h is first used as a screening condition. Aseptic filtration through a 0.22 µm PVDF membrane with a validated bubble point ≥ 3.2 bar is then selected when screening loss exceeds 1.5%. The solution is filled into Type I borosilicate glass vials complying with USP 660, and headspace oxygen is reduced to ≤ 1.0% v/v by nitrogen flushing before stoppering. For multidose presentations, benzyl alcohol at 1.5% v/v is considered only after species-specific toxicity clearance; single-dose vials avoid antimicrobial preservatives entirely. Endotoxin control is measured by Ph. Eur. 2.6.14, with a release limit of ≤ 0.5 EU/mg of amidocarb. The terminal product is a sterile solution for injection, and the absence of visible particles is verified according to Ph. Eur. 2.9.20. A critical boundary is the interaction between phosphate buffers and trace divalent cations in ampoule glass; if phosphate is used, published data for amidocarb-specific pH drift is limited, so stability studies under accelerated storage at 40 °C/25% RH for 3 months should include pH, assay, and particulate matter monitoring.

Low-Dose Capsule Filling: Flow Function Coefficient and Segregation Boundaries

Capsule filling on a Bosch GKF 700 or MG2 Planeta requires a powder bed with a flow function coefficient (ffc) above 4.0; batches below this threshold exhibit weight variation exceeding ± 3.0% at machine speeds above 60,000 capsules/h. For a 50 mg amidocarb capsule in a size 3 hard gelatin shell, a direct fill weight of 200 mg is maintained to retain die volume consistency. A representative blend contains 25.0 wt% amidocarb, 59.0 wt% lactose monohydrate, 10.0 wt% pregelatinized maize starch, 1.0 wt% talc, and 0.5 wt% colloidal silicon dioxide. The glidant is added only during the final 5 min of blending; longer high-shear mixing after silica addition overrides electrostatic charge control and reduces bulk density from 0.58 g/cm³ to 0.49 g/cm³. API segregation is assessed after 10 min of vibration at 40 Hz using a powder segregation tester; the relative standard deviation across top, middle, and bottom fractions should remain below 2.0%. Moisture is held at 30–40% RH in the encapsulation suite because higher ambient humidity increases shell brittleness and lowers fill weight reproducibility. The final capsule meets disintegration limits under USP 701 and shows not less than 75% release in 45 min under USP 711 medium 0.1 N HCl. The end product is packaged in HDPE bottles with desiccant canisters if the API is hygroscopic; published sorption data for amidocarb is limited, so the desiccant is required when moisture uptake exceeds 0.5% after 24 h at 40 °C/75% RH.

Veterinary oral powders containing amidocarb are distributed as unit-dose sachets or bulk tubs, and the primary manufacturing risk is segregation of the API from a coarse dextrose or lactose carrier during filling. A carrier with a sieve fraction of 100% passing 500 µm and not more than 25% passing 75 µm according to Ph. Eur. 2.9.12 reduces API pocketing in the screw feed. The typical unit-dose powder contains 100 mg amidocarb per 5 g, equivalent to 2.0 wt%, blended with dextrose anhydrous and 0.3 wt% colloidal silicon dioxide. Mixing is performed in a 500 L ribbon mixer at 15 rpm for 12 min; uniformity is assessed according to Ph. Eur. 2.9.40, with an acceptance value not exceeding 15.0. Because oral powders are often dosed in feed or water, the presence of hydrophobic fines may impair wetting; a wetting agent is therefore added at 0.1–0.2 wt% polysorbate 80 in the dry blend before filling. Loss on drying is controlled at not more than 1.5% after 4 h at 60 °C according to Ph. Eur. 2.2.32; moisture above this value promotes caking in aluminium sachets under tropical storage. Filling is carried out on a vertical form-fill-seal line with a target fill weight of 5.00 g ± 0.15 g, and heat-seal integrity is tested at a vacuum of -0.8 bar for 30 s with no leaks. The end product is a free-flowing oral powder for reconstitution or direct top-dress use.

Fluid-Bed Granulation Moisture Endpoint and Binder Viscosity

During fluid-bed granulation, batch-to-batch variability arises from the interaction between inlet air dew point, spray rate, and binder solution viscosity. For amidocarb granular formulations intended for sachet or compressed tablet feed, a top-spray fluid bed equipped with a 1.2 mm two-fluid nozzle is used with an inlet air temperature of 65 °C, product temperature of 32 °C, and spray rate of 40 g/min per kg of dry powder. The binder is 5% w/w povidone K30 in purified water, with a viscosity of 8–12 mPa·s at 25 °C; higher viscosity creates oversized agglomerates above 1,000 µm, while lower viscosity produces fragile granules with friability above 1.5%. The granulation endpoint is controlled by loss-on-drying at 1.5–2.5% after 10 min at 85 °C on a Mettler Toledo HR83 moisture analyzer. A representative formula includes 30.0 wt% amidocarb, 54.0 wt% lactose monohydrate, 10.0 wt% microcrystalline cellulose, 5.0 wt% pregelatinized starch, and 1.0 wt% crospovidone; PVP K30 binder solution is added to a dry-basis content of 3.0 wt%. Dried granules are milled through an 800 µm Conidur screen; the D50 particle size is held between 180 µm and 300 µm. Segregation potential is checked using Ph. Eur. 2.9.40 for content uniformity of the powder blend, with an acceptance value not exceeding 15.0. Final sachet filling uses 2.5 g granules containing 750 mg amidocarb, and the sachet paper/aluminium/polyethylene laminate is chosen because the API is protected from light if photostability data shows 5% loss after 1.2 million lux·h under ICH Q1B conditions. This configuration is then compressed into tablets or filled into sachets.

Because carryover risk dominates medicated feed line performance, premix manufacturing with amidocarb API must satisfy 21 CFR 225.1 current good manufacturing practice for medicated feeds. The API is first blended with a carrier such as ground corn cob, wheat middlings, or calcium carbonate until the theoretical concentration is 20 g/kg, then diluted into complete feed at 100–200 mg/kg depending on the target species. A ribbon mixer with a 20% coefficient of variation is used; sampling at 10 points with a grain thief should show an active concentration CV below 10.0% by an HPLC method. Electrostatic attachment of micronized amidocarb to mixer walls can create residual concentrations above 5 mg/kg in the next batch if dry cleaning only is used. Therefore, the premix includes 1.5% w/w food-grade mineral oil to reduce dust and surface adhesion. Screen analysis of the final premix requires 100% through a 2,000 µm sieve and not less than 90% through a 500 µm sieve. Stability in feed is monitored by exposing a 25 kg paper bag with polyethylene inner liner to 25 °C/60% RH for 6 months; assay loss greater than 8.0% triggers use of foil-lined bags or a lower storage temperature. The terminal premix is a free-flowing tan or off-white granular powder, and bulk density is controlled between 0.45 g/cm³ and 0.60 g/cm³ to ensure metering in feed mills.

When pH Adjustment Precedes Antioxidant Addition in Oral Solutions

When amidocarb is dissolved in oral vehicles for drench or drinking water administration, the sequence of excipient addition directly affects chemical stability. The API is first dispersed in 60% of the purified water volume, and pH is adjusted to 6.0–6.5 with 0.1 M citric acid or sodium hydroxide before adding antioxidant and preservative. If sodium metabisulfite 0.1% w/v is added before pH adjustment, the transient acidic local pH can reduce assay recovery by more than 4% under accelerated conditions at 40 °C for 30 days. A representative oral solution contains 5.0 g amidocarb per 100 mL, 20% w/v propylene glycol, 15% w/v glycerol, 0.1% w/v sodium benzoate, 0.1% w/v sodium metabisulfite, and 0.05% w/v disodium edetate. The pH is maintained with a 10 mM citrate buffer to limit drift to ± 0.2 units during 24-month storage at 25 °C. The solution is filtered through a 5 µm polypropylene capsule before filling into amber PVC-free bottles; light protection is required if photostability studies show total degradants above 1.0% at 1.2 million lux·h. The filling line uses nitrogen sparging to keep dissolved oxygen below 1.0 ppm, and continuous in-line check is performed by near-infrared rather than periodic sampling. The end product is a clear solution with a specific gravity between 1.02 g/mL and 1.08 g/mL, dosed by calibrated drench gun or mixed into drinking water at a dilution ratio of 1:500 to 1:1000 depending on the prescribed daily intake.